Monoclonal antibodies to LAG3, such as relatlimab (BMS-986016), LAG525, BI754111, MK-4280, Sym022, TSR-033, REGN3767, and INCAGN2385-101 are currently undergoing phase I and II clinical trials as monotherapy or combination therapy with anti-PD-1/PD-L1 mAbs to treat multiple myeloma, SCLC, NSCLC, gastric/esophageal adenocarcinoma, and CRC. Here, PDCD1 is linked to non-small cell lung carcinoma.